历经周期性波动的一年里,疫苗的创新真相摆在诸多入局者面前:选技术路径,稍不注意会高度雷同;做研发,比做创新药更需耐力和长期投资;做商业化,或很快陷入产能过剩和“价格战”黑洞;想出海,又因使用群体特点和各国公共卫生战略差异,被加上若有似无的政策关隘,比新药出海难走得多。信心究竟从哪来?首要从“活”过来的创新者里寻找。康希诺在过去两年里不乏一些争议,主要是对其业绩波动的担忧,及其创新疫苗商业化前景是否...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
No relevant data is available
If the download button clicks without skipping, click on the top right menu and select "Open in Browser."